NasdaqGM - Nasdaq Real Time Price USD

MediciNova, Inc. (MNOV)

1.4900

+0.0100

+(0.68%)

At close: April 23 at 4:00:00 PM EDT

1.5400

+0.05

+(3.36%)

Pre-Market: 8:00:00 AM EDT

We Think MediciNova (NASDAQ:MNOV) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Simply Wall St. 4 days ago

MNOV
+0.68%
MediciNova To Participate in D. Boral’s Capital Global Conference on May 14, 2025

LA JOLLA, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announces that their CEO, Yuichi Iwaki, MD, Ph.D., and CBO, David H. Crean, Ph.D., will be participating in investor meetings at D. Boral Capital’s, Inaugural DBC Conference on May 14, 2025 at the Plaza Hotel, New York City. The conference will bring together public and p

GlobeNewswire 9 days ago

MNOV
+0.68%
First Patient Enrolled in NIH-Funded Expanded Access Program (EAP) Trial to Evaluate MN-166 in Amyotrophic Lateral Sclerosis (ALS) Patients

LA JOLLA, Calif., April 08, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced enrollment of the first patient in the NIH-funded Expanded Access Program (EAP) trial to evaluate MN-166 (ibudilast) in patients with Amyotrophic Lateral Sclerosis (ALS). This significant milestone marks the beginning of a critical trial aimed at providing access

GlobeNewswire 15 days ago

MNOV
+0.68%
US Exchange Penny Stocks To Watch In January 2025

The U.S. stock market has recently experienced volatility, with the Nasdaq Composite and S&P 500 indices declining sharply due to concerns over China's advancements in artificial intelligence. Amidst these fluctuations, investors are increasingly exploring diverse opportunities, including penny stocks—an investment area that continues to intrigue despite its somewhat outdated terminology. These stocks often represent smaller or newer companies and can offer a blend of affordability and growth...

Simply Wall St. 2 months ago

VNDA

MNOV
+0.68%
ZNTL
US Penny Stocks To Watch In December 2024

As the U.S. stock market navigates a volatile landscape marked by benign inflation data and fluctuating interest rate expectations, investors are keenly observing opportunities across various sectors. Penny stocks, though often associated with speculative ventures, can offer unique value when supported by strong financials and growth potential. This article will explore three penny stocks that stand out for their robust financial health, presenting intriguing possibilities for investors...

Simply Wall St. 4 months ago

AIHS

MNOV
+0.68%
MNOV: Encouraging Interim Analysis for Phase 2b/3 ALS Trial…

By David Bautz, PhD NASDAQ:MNOV READ THE FULL MNOV RESEARCH REPORT Business Update Encouraging Interim Results from Phase 2b/3 COMBAT-ALS Trial On December 5, 2024, MediciNova, Inc. (NASDAQ:MNOV) announced a poster presentation at the 35 th International Symposium on ALS/MND would feature a study update and interim analysis results from the ongoing Phase 2b/3 COMBAT-ALS trial of MN-166

Zacks Small Cap Research 4 months ago

MNOV
+0.68%
MediciNova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS (COMBAT-ALS Clinical Trial) at the 35th International Symposium on ALS/MND

LA JOLLA, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announces the study update and interim analysis results from the Company’s COMBAT-ALS Phase 2b/3 clinical trial of MN-166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS) will be presented at the 35th International Symposium on ALS/MND held December 6-8, 2024 in Montreal,

GlobeNewswire 4 months ago

MNOV
+0.68%
MNOV: Monetary Damages Due Following Sanofi/Novartis Patent Dispute Settlement…

By David Bautz, PhD NASDAQ:MNOV READ THE FULL MNOV RESEARCH REPORT Business Update Monetary Damages Due from Sanofi/Novartis Litigation Settlement On November 11, 2024, MediciNova, Inc. (NASDAQ:MNOV) announced a settlement in the patent litigation brought by Genzyme Corporation, a subsidiary of Sanofi, against Novartis. The litigation included a claim for infringement of U.S. Patent No.

Zacks Small Cap Research 4 months ago

MNOV
+0.68%
SNY

NVS
MediciNova CEO Yuichi Iwaki Provides Corporate Update in Letter to Stockholders

NIH-funded Phase 2-3 ALS Expanded Access study expands reach of MediciNova’s ongoing COMBAT-ALS trial and provides illustration of Company’s development strategyLA JOLLA, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875) focused on development of novel anti-inflammatory treatments for neurodegenerative diseases, malignant brain cancers, an

GlobeNewswire 5 months ago

MNOV
+0.68%
MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver

LA JOLLA, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), announces that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a pending patent application for MN-001 (Tipelukast) to cover "Method to Decrease Triglyceride Synthesis in a Liver of a Subject." The allowed claims cover a groundbreaking

GlobeNewswire 5 months ago

MNOV
+0.68%
MediciNova: Q3 Earnings Snapshot

LA JOLLA, Calif. AP) — MediciNova Inc. MNOV) on Wednesday reported a loss of $2.9 million in its third quarter.

Associated Press Finance 5 months ago

MNOV
+0.68%
3 US Penny Stocks With Market Caps Over $40M To Consider

As the U.S. stock market takes a breather following a post-election rally, investors are keenly observing opportunities that might arise in different sectors. Penny stocks, despite their somewhat outdated name, remain relevant as they often represent smaller or newer companies with potential for growth. With strong financial foundations and solid fundamentals, these stocks can offer valuable opportunities for those willing to explore beyond the well-trodden paths of larger firms.

Simply Wall St. 5 months ago

IKNA

MNOV
+0.68%
RLYB
MediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis

LA JOLLA, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it was notified by Sanofi that the Sanofi/Novartis litigation was settled. Accordingly, MediciNova is entitled to receive a certain amount of monetary damages through this settlement. Further details will be provided as they become available. Yuichi Iwaki, M

GlobeNewswire 5 months ago

MNOV
+0.68%
MediciNova Announces Update of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS patients (COMBAT-ALS) at the 2024 Annual NEALS Meeting (Northeast Amyotrophic Lateral Sclerosis Consortium)

LA JOLLA, Calif., Oct. 23, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the lead Principal Investigator of this clinical trial, Björn Oskarsson, MD, FAAN presented the update of an ongoing Phase 2/3 clinical trial of MN-166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS) patients at the 2024 Annual NEALS Meeting being held virtuall

GlobeNewswire 5 months ago

MNOV
+0.68%
MediciNova (NASDAQ:MNOV) shareholders have endured a 73% loss from investing in the stock five years ago

It is doubtless a positive to see that the MediciNova, Inc. ( NASDAQ:MNOV ) share price has gained some 45% in the last...

Simply Wall St. 6 months ago

MNOV
+0.68%
MediciNova to Support NIH-Funded Expanded Access Clinical Trial to Evaluate MN166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS)

Academic group to receive a total of $22 million for the trialLA JOLLA, Calif., Sept. 30, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that the National Institutes of Health (NIH) - Neurological Disorders and Stroke (NINDS) has awarded $22 million for an intermediate size Expanded Access Protocol (EAP) to evaluate the efficacy of MN-1

GlobeNewswire 6 months ago

MNOV
+0.68%
MNOV: MN-166 to be Evaluated in NIH-Sponsored Expanded Access Trial in ALS…

By David Bautz, PhD NASDAQ:MNOV READ THE FULL MNOV RESEARCH REPORT On September 30, 2024, MediciNova, Inc. (NASDAQ:MNOV) announced that MN-166 (ibudilast) will be evaluated in an Expanded Access Protocol (EAP) trial to evaluate its efficacy in patients with amyotrophic lateral sclerosis (ALS). The EAP is being supported through a $22 million grant from the National Institutes of Health (NIH) –

Zacks Small Cap Research 6 months ago

MNOV
+0.68%
MediciNova Announces Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial Accepted for Poster Presentation at the 35th International Symposium on ALS / MND

LA JOLLA, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that an abstract regarding a clinical trial of MN-166 (ibudilast) in the treatment of Amyotrophic Lateral Sclerosis (ALS), COMBAT-ALS study has been selected for a poster presentation at the 35th International Symposium on ALS / MND to be held December 6-8, 2024

GlobeNewswire 7 months ago

MNOV
+0.68%
MediciNova Announces Acceptance of Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial for Presentation at the 2024 Annual NEALS (Northeast Amyotrophic Lateral Sclerosis Consortium) Meeting

LA JOLLA, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that an abstract was accepted for presentation regarding a clinical trial of MN-166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS), COMBAT-ALS Phase 2b/ 3 study at the 2024 Annual NEALS Meeting to be held October 21-24, 2024 (a hybrid meeting in Clearwater, F

GlobeNewswire 7 months ago

MNOV
+0.68%
MNOV: Phase 3 ALS Readout in 2025…

By David Bautz, PhD NASDAQ:MNOV READ THE FULL MNOV RESEARCH REPORT Business Update Phase 3 ALS Trial Ongoing MediciNova, Inc. (NASDAQ:MNOV) is currently evaluating MN-166 (ibudilast) in a Phase 3 clinical trial for amyotrophic lateral sclerosis (ALS). The trial initiated in 2019 and, if successful, results from this trial are expected to support a New Drug Application (NDA) for MN-166 in ALS. A

Zacks Small Cap Research 7 months ago

MNOV
+0.68%

Performance Overview

Return	MNOV	S&P 500 (^GSPC)
YTD	-29.05%	-8.60%
1-Year	+12.03%	+6.02%
3-Year	-49.15%	+25.85%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

MediciNova, Inc. (MNOV)

We Think MediciNova (NASDAQ:MNOV) Can Afford To Drive Business Growth

MediciNova To Participate in D. Boral’s Capital Global Conference on May 14, 2025

First Patient Enrolled in NIH-Funded Expanded Access Program (EAP) Trial to Evaluate MN-166 in Amyotrophic Lateral Sclerosis (ALS) Patients

US Exchange Penny Stocks To Watch In January 2025

US Penny Stocks To Watch In December 2024

MNOV: Encouraging Interim Analysis for Phase 2b/3 ALS Trial…

MediciNova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS (COMBAT-ALS Clinical Trial) at the 35th International Symposium on ALS/MND

MNOV: Monetary Damages Due Following Sanofi/Novartis Patent Dispute Settlement…

MediciNova CEO Yuichi Iwaki Provides Corporate Update in Letter to Stockholders

MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver

MediciNova: Q3 Earnings Snapshot

3 US Penny Stocks With Market Caps Over $40M To Consider

MediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis

MediciNova Announces Update of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS patients (COMBAT-ALS) at the 2024 Annual NEALS Meeting (Northeast Amyotrophic Lateral Sclerosis Consortium)

MediciNova (NASDAQ:MNOV) shareholders have endured a 73% loss from investing in the stock five years ago

MediciNova to Support NIH-Funded Expanded Access Clinical Trial to Evaluate MN166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS)

MNOV: MN-166 to be Evaluated in NIH-Sponsored Expanded Access Trial in ALS…

MediciNova Announces Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial Accepted for Poster Presentation at the 35th International Symposium on ALS / MND

MediciNova Announces Acceptance of Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial for Presentation at the 2024 Annual NEALS (Northeast Amyotrophic Lateral Sclerosis Consortium) Meeting

MNOV: Phase 3 ALS Readout in 2025…

Performance Overview